Business Context and Reporting Period
This Form 8-K is a current report filed by Nile Therapeutics, Inc. (not Capricor Therapeutics, Inc., as indicated in the metadata) on June 4, 2010, covering an event that occurred on June 1, 2010. The filing addresses a regulatory notice regarding the company's stock listing status on The Nasdaq Stock Market.
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, or debt figures. The only quantitative metric disclosed is the stock price performance:
- Minimum Bid Price: The common stock traded below $1.00 per share for 30 consecutive business days prior to June 1, 2010.
Material Changes
The primary material event is the receipt of a notice from Nasdaq stating the company is not in compliance with Marketplace Rule 5550(a)(2) due to the sustained low bid price. This triggers a potential delisting process if compliance is not restored.
Outlook, Risks, and Management Commentary
- Compliance Period: Nasdaq has granted an initial grace period of 180 calendar days, ending on November 29, 2010, to regain compliance.
- Compliance Criteria: To regain compliance, the stock must close at $1.00 per share or more for a minimum of 10 consecutive business days before the deadline.
- Future Actions: If compliance is not met by the deadline, the company may be eligible for an additional 180-day grace period if it meets other initial listing standards. Failure to do so will result in delisting notification, subject to appeal.
- Management Response: The company intends to actively monitor the bid price and consider available options to resolve the deficiency but has not yet determined specific actions.
Investor Verification Checklist
- Verify the current trading price of Nile Therapeutics, Inc. common stock to assess proximity to the $1.00 threshold.
- Monitor the company's stock performance for the next 10 consecutive business days to determine if the compliance window is met.
- Review the attached press release (Exhibit 99.1) for any additional details on potential corporate actions (e.g., reverse stock splits) to address the bid price deficiency.
- Confirm the company's status regarding other Nasdaq initial listing standards in case the initial grace period expires.